Fatal insomnia
| Fatal Insomnia | |
|---|---|
| Other names | Thalamic Creutzfeldt-Jakob disease |
| Longitudinal comparison of 18F-FDG PET/MRI in brain in a patient with fatal insomnia, demonstrating normal brain parenchyma on MRI, but prominent hypometabolism of the thalamus. The top row of images shows baseline brain scans of the patient; the bottom row shows follow-up brain scans taken three and a half months later. A,B and G,H show MRI-FLAIR; C,D and I,J show DWI; E,F and K,L show fusion imaging (T1WI and SUVR map of 18F-FDG PET). | |
| Specialty | Neurology, psychiatry, sleep medicine, neuropathology |
| Symptoms | Progressive insomnia, ataxia, double vision, cachexia, high blood pressure, excessive sweating, fever, agrypnia excitata, panic attacks, dementia, delusions, phobias, tachycardia, vivid dreams |
| Complications | Permanent state of hypnagogia later in the illness, heart attack |
| Usual onset | 45–50 years old |
| Duration | 18 months (average) |
| Types | Fatal familial insomnia, sporadic fatal insomnia |
| Causes | PrPCJD type 2 (Genetic mutation (fCJD D178N-129MM/MV), sporadic form (sCJDMM2-T, very rare)) |
| Risk factors | Family history |
| Diagnostic method | Suspected based on symptoms, supported by sleep study, PET scan and genetic testing (if familial form is suspected) |
| Differential diagnosis | Creutzfeldt-Jakob disease, Morvan's syndrome |
| Prevention | Gene editing of children at risk |
| Treatment | Supportive care |
| Medication | None |
| Prognosis | Invariably fatal |
| Frequency | 70 families worldwide are known to carry the gene associated with the disease, 37 sporadic cases diagnosed (as of 20 September 2022) |
| Deaths | <1 per year |
Fatal insomnia is a rare, invariably fatal neurodegenerative disease and prion disease characterized by progressive and unrelenting insomnia, autonomic dysfunction, and rapid cognitive decline. The condition is classified into two distinct forms based on its underlying etiology. The vast majority of diagnoses are hereditary cases known as fatal familial insomnia (FFI), which stem directly from a dominant mutation in the PRNP gene. The remaining minority of cases occur sporadically without any underlying genetic mutation, a variant recognized clinically as sporadic fatal insomnia (sFI).
The hallmark symptom of fatal insomnia is profound trouble sleeping, which typically begins as a gradual disruption of the sleep cycle but worsens relentlessly over time. Eventually, affected patients enter a permanent state of complete sleep inability clinically termed agrypnia excitata. This profound state of sustained wakefulness and sleep deprivation leads directly to other severe neurological symptoms, including speech problems, impaired motor coordination, and rapidly advancing dementia. The disease is universally fatal, typically resulting in the patient's death within a few months to a few years following the onset of symptoms, and there is currently no known disease-modifying treatment available in modern medicine.